Subject Index

Access restrictions, in Japan, 28–29
Access rules, 4, 44; cost sharing in insurance and, 58–61; in developed world, 65; impact of nonfinancial restrictions, 64–65; in Japan, 22–24; nonfinancial restrictions and, 61–64

Acute myocardial infarctions (AMIs), 8; data for study of, 171-78; discussion of study results for, 185-87; effects of high-tech treatments on quality of care for, 178-81; effects of low-tech treatments on quality of care for, 181–85; empirical specification and measurements for study of, 169-70; estimated cost of low-quality care for, 200-203; factors affecting adoption of highquality care for, 203-5; in Japan, 10-11; in Japan and U.S., 165-66; measuring technological diffusion for treatment of, 199-200; previous research on, 166-68; in United States, 10-11; use of beta-blockers for, 196; use of pharmaceuticals and, 196–97. See also Coronary artery bypass graft (CABG) surgery; Percutaneous transluminal coronary angioplasty (PTCA) procedures

Aging, fertility and, 75
Aging crisis, 5, 69
AMI. See Acute myocardial infarctions
(AMIs)

Angioplasty. See Percutaneous transluminal coronary angioplasty (PTCA) procedures

Average life expectancies, in Japan, 19

Beta-blockers, 196
Bill of Rights, Patient's, 64
Birth rates, 75
Bundled payment system, in Japan, 29–30
Bypass surgery, 56

CABG surgery. See Coronary artery bypass graft (CABG) surgery
Canada, restrictions on utilization in, 65
Capitation payment systems, 54–55
Cardiac catheterization, 55–56, 166–67, 169. See also Acute myocardial infarctions (AMIs)
Caregiving. See Work, caregiving and CCP. See Cooperative Cardiovascular

CCP. See Cooperative Cardiovascular
Project (CCP)

Cigarette smoking, 229. See also Nicotine replacement therapy (NRT); Smoking cessation

Citizens' Health Insurance (CHI), 22–24, 35, 36, 38–39

Commonwealth Fund, 214
Conjoint analysis (CA), 231
Contingent valuation methods (CVMs), 231
Cooperative Cardiovascular Project (CCP),
11, 166, 185–86

- Coronary artery bypass graft (CABG) surgery, 115, 123, 167; emergency, as indicator of quality of health care, 135–37, 136t; hospital volume and, 116. See also Percutaneous transluminal coronary angioplasty (PTCA) procedures
- Cost sharing: in Medicare, 59–61; private insurance and, 58–59; tax system and, 59

Coverage rules, 4, 21, 44

Custodial care, 211

Czech Republic, 6; elderly in, 75; medical care spending increases in, 76–77

Death rates, volume effect and, 115–16 Demographics, medical spending and, 74–77

Diagnosis-related groups (DRGs), 22, 55-56, 186

Elasticity of medical care, 45

Elderly, in U.S.: care of, 209, 210–12; insurance coverage for, 46–49; long-term care and, 9–10. See also Long-term care insurance system, in U.S.; Long-term health care; Medicaid; Medicare

Emergency coronary artery bypass graft (CABG), 135–37, 136t

Employer-provided insurance plans, 48; payment of premiums under, 50 Employment. *See* Work, caregiving and End-of-life care, 20

Fagerstrom Test for Nicotine Dependence (FTND), 235, 235n5

Family doctor system, in Japan, 28–29 Family Medical Leave Act (1993), 210, 210n1

Fee-for-service payment systems, 54 Fertility rates, 75

Fixed costs, of medical care, 53–54 Forecasts, for medical spending, 70–74

GDP. See Gross domestic product (GDP), medical spending as share of

Geography, and quality of health care, in U.S., 195-97. See also Quality of health care, U.S.

GMHI. See Government-Managed Health Insurance (GMHI)

Government-Managed Health Insurance (GMHI), 22–24, 35, 36, 38

- Greece, 6; elderly in, 74; medical care spending increases in, 76–77
 Gross domestic product (GDP) medical
- Gross domestic product (GDP), medical spending as share of, 45, 46f

HCFA. See Home Care Financing Administration (HCFA)

Health, measuring, 45

Health and Retirement Study (HRS), 214–15

Health care quality. See Quality of health care

Health Care Quality Improvement Program (HCQIP), 185

Health care services, international comparison of indicators, 25t

Health care spending. See Medical spending Health care systems, Japan vs. U.S., 2-8 Health expenditures. See Medical spending

Health insurance coverage, in U.S., 46–52; access rules for, 58–61; funding for, 49–51; gradations in, 51–52; nonfinancial barriers to, 61–65; private, 51–52; reimbursement systems of, 53–58; sources of, 48, 48t

Health insurance schemes, in Japan, 21–24; access rules for, 22; coverage rules for, 21; effect of population aging on, 20; reimbursement system for, 21–22

Health insurance system, in Japan: financing, 86–92; introduced, 83–86; microsimulation model of, 92–94; simulation results of different scenarios for, 94–107

Health maintenance organizations (HMOs), 51–52, 62–63; enrollment in, 64; mechanisms to limit utilization employed by, 63–64; network model, 62t, 63

Health System for the Elderly (HSE), 24, 35, 36, 38–39

Heart attacks. See Acute myocardial infarctions (AMIs)

Heart disease: in Japan, 11; in U.S., 11 High-tech treatments, 166; effects of, quality of care, 178–81

HMOs. See Health maintenance organizations (HMOs)

Home Care Financing Administration (HCFA), 166, 166n1

Home health care: informal, 212; Medicare restrictions of coverage of, 211

Home help industry, in Japan, 9; about, 147–49; data for study of, 150–52; pre-

vious research on, 149–50; results for efficiency of, 157–59; results for quality of services in, 155–57; theoretical models for, 152–55

Hospital beds per capita, Japan vs. U.S., 1 Hospital referral regions (HRRs), 200 Hospital stays, in Japan, 31 Hospital volume, 115–17 Hospital volume effect, 128–30 HRRs. See Hospital referral regions (HRRs) HRS. See Health and Retirement Study (HRS)

HSE. See Health System for the Elderly (HSE)

Inclusive payment system, in Japan, 29–30 Indemnity insurance, 61, 62t Independent practice associations (IPAs),

Informal home health care, 212. See also Home health care

Inpayment insurance (Part A) of Medicare, 49–50

Insurance coverage. See Health insurance coverage

Insurance premiums, payment of, 50 IPAs. See Independent practice associations (IPAs)

Italy, 6; birth rate for, 75; elderly in, 74, 75; medical care spending increases in, 76-77

Japan: access restrictions in, 28–29; access rules in, 22-24; acute myocardial infarctions in, 165-66; AMI cases in, 10-11; AMI patients in, 8; average life expectancy in, 19; birth rate for, 75; burden on employees and national treasury to finance insurance scheme for elderly in, 88–91; cigarette smoking and mortality in, 229; costs of medical services in, 24-25; coverage rules in, 21; effects of 2003 health reform in, 35-40; elderly in, 74; family doctor system in, 28-29; health care system in, 2-8, 17-18; health expenditures in, 19; health insurance schemes in, 21-24; health reforms of 2003 in, 35-40; health spending in, 24–25; inclusive payment system in, 29-30; limitations on health services in, 31-32; long-term care insurance system in, 9-10, 32-35;

medical practice patterns in, 8–13; medical system reforms in 1990s in, 25–32; microsimulation model for medical expenses in, 92-94; national medical expenditures in, 86-88; nursing care payments in, 34–35; pharmacy services in, 32; population aging in, 18-20; price elasticity of demand for medical in, 26-28; problems in current health insurance system of, 91-92; quality of care in, 8-13; quality of medical services in, 24-25; referral system in, 28; reimbursement system in, 21-22; restriction of free access in, 28-29; simulation results under different scenarios for medical expenses, 94–107; smoking cessation in, 14–15; spending on health care in, 1; supply controls in, 30-31; welfare in, 33. See also Acute myocardial infarctions (AMIs); Health insurance system, in Japan; Home help industry, in Japan; Percutaneous transluminal coronary angioplasty (PTCA) procedures; Quality of health care, Japan vs. U.S.; Smoking cessation

Japanese Medical Association, 32 Japanese Society of Interventional Cardiology (JSIC) data set, 121, 167; sensitivity analysis using, 138–43

Korea, elderly in, 75

Life expectancy: as measure of health, 45; medical spending and, 45–46, 47f; in OECD countries, 45, 47f

Long-term care insurance system, in Japan, 32–35; overview of, 33–34; proposed improvements for, 34–35

Long-term care insurance system, in U.S., 212. See also Elderly, in U.S.

Long-term health care: cross-sectional examination results for, 216–17; data for study of, 214–16; theoretical framework for analyzing decision to provide, 213–14; transitions between work and caregiving for, 217–21

Low-tech treatments, 166

Magnetic resonance imaging (MRI) machines, Japan vs. U.S., 1 Managed care: changes in enrollment in, 63t, 64; in Medicare, 52 Managed care plans, 61, 62t; health maintenance organizations, 62–63; independent practice associations, 63; managed indemnity insurance policies, 61; preferred provider organizations, 62

Managed indemnity insurance policy, 61, 62t

MAR. See Medical arms race (MAR) Marginal costs, of medical care, 53–54 Medicaid, 46–48; home health care and, 211–12; services covered by, 51–52, 51t

Medical arms race (MAR), 149

Medical care: fixed costs of, 53–54; marginal costs of, 53–54; price elasticity of demand for, 26–29

Medical care systems: interactions in, 44; participants in, 43–44; performance of, across countries, 44–46. See also Access rules; Coverage rules; Reimbursement systems

Medical services, in Japan, 24-25

Medical spending: about, 69–70; demographics and, 74–77; forecasting, 70–74; implications of increasing, 78–79; in Japan, 19–25; Japan vs. U.S., 1–2; life expectancy and, 45–46, 47f; population aging and, 19–24; as share of gross domestic product, 45, 73f; sustainability of, 78–80; technological change and, 77

Medical technology, 73

Medicare, 46–49; compensation for surgery and, 198; cost sharing in, 59–60; coverage by Medicare for, 211; custodial care coverage by, 211; funding of, 49–50; gaps in coverage by, 210–11; home health care and, 211; managed care in, 52; nonfinancial restrictions of, 61; prospective payment system of, 55; reimbursement systems of, 55; services covered by, 51–52, 51t

Medicare crisis, 5, 69

Medigap insurance, 60

Microsimulation model, of Japanese health insurance system, 92–94; simulation results of different scenarios for, 94– 107

Misuse of procedures, quality of care and,

Mortality rates, volume effect and, 115–16 MRI. See Magnetic resonance imaging (MRI) machines, Japan vs. U.S.

National Family Support Program, 210n1 Network model HMOs, 62t, 63

Nicorette, 233-34, 233t

Nicotine gum: attitudes toward, 232–34; estimation of demand for, 234–37

Nicotine replacement therapy (NRT), 14–16, 230; cost benefit analysis for, 237–41; data for study of, 232–34; demand for, in Japan, 230–31; types of, 230. See also Smoking cessation

Nonfinancial restrictions: impact of, 64; in Medicare, 61; in private insurance, 61-64

NRT. See Nicotine replacement therapy (NRT)

Nursing care insurance. See Long-term care insurance system, in Japan; Long-term care insurance system, in U.S.

Nursing homes. *See* Skilled nursing facilities (SNFs)

Obesity rates, Japan vs. U.S., 1–2 Old age insurance crisis, 5, 69

Older Americans Act Amendments (2000), 210, 210n1

Overuse of procedures, quality of care and, 195

Part A (inpayment insurance) of Medicare,

Passive smoking, 229

Patient's Bill of Rights, 64

Payment systems: capitation, 54–55; feefor-service, 54; salary, 54. See also Reimbursement systems

Percutaneous transluminal coronary angioplasty (PTCA) procedures, 56, 167, 198; data and models for, 120-25; data overview for patients undergoing, 125-28; hospital mortality vs. physician mortality for, 128; hospital volume and mortality rates for, 126, 126f; hospital volume effect for, 128-30, 129t; literature review of, 115-18; physician volume and mortality rates for, 126, 127f; physician volume effect for, 130-33, 131t; physician volume effect with hospital volume for, 133-35, 134t; physician volume vs. hospital volume for, 126-27, 127f; recommended number of, in Japan, 113-14; recommended number of, to ensure quality, in U.S.,

113–14; research strategy for, 118–20; volume and outcome relationships in Japan for, 8–9. See also Coronary artery bypass graft (CABG) surgery; Volume effect

Pharmacy services, in Japan. See Prescription drug coverage

Physician volume, 116-17

Physician volume effect, 130-35

Point of service (POS) options, 63-64

Population aging, in Japan, 18–20; effect of, on health insurance plans, 20; health expenditures and, 19–24

Preferred provider organizations (PPOs), 62, 62t

Prescription drug coverage: in Japan, 32; in U.S., 52

Price elasticity, of demand for medical care in Japan, 26–28

Prospective payment system (PPS), 55

PTCA. See Percutaneous transluminal coronary angioplasty (PTCA) procedures

Public insurance, in U.S., 48–49. See also Medicaid; Medicare

Public Nursing Insurance Act (1997), 9

Quality of health care, Japan vs. U.S.: data for study of, 171–78; effects of hightech treatments on, 178–81; effects of low-tech treatments, 181–85; emergency CABG as indicator of, 135–37, 136t; for heart attack patients, 165–66; previous research on, 166–68; research design for, 169–70; results for study of, 178–85; underuse, overuse, and misuse in, 195

Quality of health care, U.S.: effects of high, for AMI patients, 203–5; effects of low, for AMI patients, 200–203; empirical measures of technology adoption and, 199–200; estimate cost of low, for AMIs, 200–203; factors affecting adopting of high, for AMIs, 203–5; geography and, in U.S., 195–97; models of technology adoption and, 197–99

Referral systems, in Japan, 28 Reimbursement systems, 4, 21–22, 44; incentives and, 56–58; of Medicare, 55; in U.S., 53–56. *See also* Payment systems

Reperfusion therapy, 197–98

Salary systems, 54

Skilled nursing facilities (SNFs), Medicare coverage and, 211

SMHI. See Society-Managed Health Insurance (SMHI)

Smoking. See Cigarette smoking; Nicotine replacement therapy (NRT)

Smoking cessation: attitude toward, 232–33, 232t; cost-benefit analysis of policy for, 237–41; in Japan, 14–16, 229; long-run effects of, 239–41; methods of, 233, 233t. See also Nicotine replacement therapy (NRT)

Smoking rates, Japan vs. U.S., 2

SNFs. See Skilled nursing facilities (SNFs), Medicare coverage and

Social Security crisis, 5, 69

Society-Managed Health Insurance (SMHI), 22–24, 35, 36, 38

Spain, 6; elderly in, 75; medical care spending increases in, 76–77

Stop-loss, 58-59

Supply controls, in Japan, 30-31

Sweden, elderly in, 74

Switzerland, 6; medical care spending increases in, 76–77; medical spending as share of GDP in, 45

Technological change, forecasting medical spending and, 77

Technological diffusion, measuring, for treatment of AMIs, 199–200

Technology adoption and quality of care: empirical measures of, 199–200; models of, 197–99

Total fertility ration (TFR), 18–19 Turkey, medical care spending increases in, 76–77

Underuse of procedures, quality of care and, 195–96

United Kingdom: medical care spending increases in, 76–77; medical spending as share of GDP in, 45

United States: acute myocardial infarctions in, 165-66; AMI cases in, 10-11; AMI patients in, 8; care of elderly in, 210-12; elderly in, 74; funding for health insurance coverage in, 49-51; health care systems in, 2-8; health insurance coverage in, 46-49; heart disease in, 11, 165; insurance coverage in, 46-52;

United States (continued)

medical care system in, 57–58; medical practice patterns in, 8–13; medical spending as share of GDP in, 45; medical technology in, 73; public insurance in, 48–49; quality of care in, 8–13; spending on health care in, 1. See also Medicaid; Medicare; Quality of health care; Quality of health care; Quality of health care, Japan vs. U.S.

Utilization reviews, 61-62

Volume effect: channels for, 119; conceptual framework for understanding, 117–18; data and models for, 120–25; data overview for, 125–28; defined, 113; hos-

pital, 128–30; linear vs. nonlinear, 119; literature review of, 115–18; mortality rates and, 115–16; outcomes and, 117; physician, 130–35; research strategy for study of, 118–20. See also Percutaneous transluminal coronary angioplasty (PTCA) procedures

Welfare, in Japan, 33

Work, caregiving and, 13–14, 209–10; background, 210–12; cross-sectional examination of, 216–17; data for study of, 214–16; longer time horizon for studying, 221–23; multivariate analyses of, 223–26; theoretical framework for, 213–14; transitions between, 217–21